XLIFE-SCIENCES-AG
31.3.2021 08:54:13 CEST | Business Wire | Press release
In 2020, Xlife Sciences AG (XLS) significantly increased its profit to 21.2 million Swiss francs compared to the previous year (1.03 million). The increase is based on the transaction and the capital appreciation of the portfolio companies Velabs Therapeutics and Araxa Biosciences. For the current year, the management expects again a significant increase in profits. For 2021, two exits and an IPO are planned for 2022.
Xlife Sciences AG looks back on a very successful 2020. With a lean cost structure of approximately 3.2 million Swiss Francs (2020: 1.5 million) as a result of the transaction and capital appreciation of Velabs and Araxa with a net profit of 21.2 million Swiss Francs. This is a very good financial result, which reflects the intrinsic value and the potential of our project portfolio, says Oliver R. Baumann, CEO of Xlife. The capital appreciation of our projects is based on external studies conducted by the consulting firm EY, following the exit in December 2020. On a positive note, Baumann also adds that at least four portfolio projects will generate revenue this year. Taking the early phase into account, this is a considerable result.
Due to the promising development of the projects, the management expects a significantly higher profit for 2021 as well. Two exit transactions are still planned for the current year. In addition, Veraxa Biotech AG will be listed on the stock exchange in 2022 at the latest. For 2022, Xlife confirms a profit target of around 60 million Swiss francs.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
Language: |
English |
Company: |
Xlife Sciences AG |
|
Klausstrasse 19 |
|
8008 Zürich |
|
Switzerland |
Phone: |
0041 44 385 84 60 |
E-mail: |
|
Internet: |
|
ISIN: |
CH0461929603 |
WKN: |
A2PK6Z |
Listed: |
Regulated Unofficial Market in Frankfurt, Munich |
EQS News ID: |
1179954 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330006176/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlightSafety International Receives FAA Approval for Virtual Aircraft Preflight Inspection with Evaluation Mode6.5.2026 16:05:00 CEST | Press release
Three aircraft programs approved, with three more expected to receive approval in 2026 FlightSafety International Inc., the global leader in aviation training and simulation technology, today announced it has received Federal Aviation Administration (FAA) approval for Virtual Aircraft Preflight Inspection (VAPI) with Evaluation Mode for three aircraft training programs: the Embraer EMB-550, Gulfstream G500/G600, and Citation Latitude. This innovative capability allows pilots in initial training to complete a 3D virtual aircraft preflight inspection while in Training Mode, with the added ability to transition directly into the flight deck, followed by Evaluation Mode, that allows pilots to do their preflight check ride portion. “VAPI represents a meaningful advancement in training innovation,” said David Penney, VP of Safety, Courseware and Regulatory Affairs, FlightSafety International. “By leveraging an immersive 3D environment, it offers pilots a more engaging and practical way to de
Riskified Unveils Next-Generation AI Suite at Ascend 2026, Empowering Merchants with Unprecedented Visibility and Control Over Ecommerce Risk6.5.2026 15:00:00 CEST | Press release
New capabilities include Riskified ARIA the AI Risk Analyst, Identity Explore 2.0, and an enhanced Decision Studio, giving merchants the power to see, understand, and act on network risk intelligence like never before Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced a major leap forward in its AI platform capabilities, introducing a powerful suite of control and empowerment tools designed to give merchant fraud teams complete visibility into risk patterns and identity behavior, conversational AI-driven insights, and the ability to surgically tailor their risk strategies. The innovation suite was announced onstage at Ascend 2026, Riskified’s premier global summit series, taking place May 4-6, 2026, at the Conrad New York Downtown in Manhattan, NY. With global ecommerce continuing to expand and losses from AI-driven fraud attacks projected to spike, particularly with the rise of agentic commerce, where AI bots may conduct transactions on b
Twilio’s Next Generation Platform: An Infrastructure Layer for Every Conversation in the Agentic Era6.5.2026 15:00:00 CEST | Press release
New platform capabilities orchestrate context-rich conversations with persistent memory across multiple channels for humans and AI agentsConversation Memory, Conversation Orchestrator, Conversation Intelligence, and Agent Connect provide the nervous system for modern customer engagement Twilio (NYSE: TWLO), the infrastructure for customer engagement in the AI era, kicked off its user conference, SIGNAL, by unveiling its next generation platform capabilities for the agentic era. Generally available today, Conversation Memory, Conversation Orchestrator, Conversation Intelligence, and Agent Connect combine to turn disparate interactions into continuous, intelligent, and personal conversations across humans, agents, and systems. “The agentic era is here. Agents are joining conversations alongside the people they represent, and modern customer engagement requires an infrastructure that serves both equally,” said Khozema Shipchandler, Chief Executive Officer at Twilio. “Twilio’s new platform
Vultr, SUSE & Supermicro Debut Unified Cloud-to-Edge Architecture for Global AI Scaling6.5.2026 14:00:00 CEST | Press release
The strategic partnership bridges the gap between regional cloud and the far edge, combining ruggedized hardware and GitOps-driven Kubernetes to streamline large-scale AI deployments Vultr, the world's largest privately-held cloud infrastructure company, in collaboration with SUSE and Supermicro, today announces a strategic architectural framework designed to solve the complexities of deploying and operating AI workloads across distributed environments. As AI moves closer to the point of data creation - from manufacturing floors to retail storefronts - organizations face significant challenges in latency, cost and operational consistency. This joint initiative provides a seamless, Cloud-to-Edge pipeline that integrates high-performance hardware, localized cloud infrastructure, and unified Kubernetes management. The partnership addresses the reality that sending all data back to a central cloud is no longer viable for real-time AI. The solution breaks down the infrastructure into three
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program6.5.2026 14:00:00 CEST | Press release
Waiv, formerly Owkin Dx, to leverage its digital pathology platform encompassing foundation models and AI methodology for ADC biomarker discovery program Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solutions across the full drug development lifecycle. Under the collaboration, Waiv will apply its end-to-end computational pathology platform to early phase data. This includes tumor microenvironment (TME) analysis across both hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained samples, as well as biomarker discovery and outcome prediction capabilities aimed at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom